SHANGHAI, China, Dec. 19 /Xinhua-PRNewswire/ -- SynTheAll Pharmaceuticals (STA), a wholly owned subsidiary of WuXi PharmaTech, today announced it has successfully passed ISO 9001:2000 audit by SGS. STA, located in Jinshan District of Shanghai, received the certification for its 250,000 square foot facility that manufactures pharmaceutical intermediates and active pharmaceutical ingredients (API) under GMP conditions.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )
SGS is the world’s leading inspection, verification, testing and certification company. SGS is recognized as the global benchmark for quality and integrity. With 42,000 employees, SGS operates a network of about 1,000 offices and laboratories around the world.
ISO is a network of the national standards institutes of 156 countries. ISO standards specify the requirements for state-of-the-art products, services, processes, materials and systems, and for good conformity assessment, managerial and organizational practice. ISO 9001:2000 is based on eight quality management principles: customer focus, leadership, involvement of people, process approach, system approach, continual improvement, fact based decision making, and mutually beneficial supplier relationships.
“SynTheAll’s ISO 9001:2000 certification exemplifies our commitment to quality and customer satisfaction as well as continuously improving our quality systems, integrating the realities of a changing world,” said Mr. Jagdish Sastry, Chief Operating Officer of SynTheAll, “We are continually using, monitoring and improving our management system and processes so as to meet or exceed customer satisfaction and delivery requirements. It is every STA employee’s ongoing concern to keep their sights on every operational detail and to enhance accuracy and efficiency.”
About WuXi PharmaTech
Shanghai-based WuXi PharmaTech Co., Ltd. offers global pharmaceutical/ bio-pharmaceutical companies diverse outsourcing services in combinatorial, medicinal, synthetic chemistry and manufacturing. Importantly, it also allows them to take full advantage of the lower research costs in China. WuXi PharmaTech’s rapidly expanding line of services ranges from early stage discovery chemistry through lead optimization chemistry, all the way to process research & development and bulk manufacture of active pharmaceutical ingredients. With the addition of a new GMP plant at Jinshan in Shanghai, WuXi PharmaTech has further increased its bulk production capacity to meet rapidly growing customer demand. WuXi PharmaTech’s strong capabilities and impressive track record enable the company to provide a broad spectrum of integrated development services from milligram to metric ton scaled active pharmaceutical ingredients, intermediates and raw materials. Currently, WuXi PharmaTech’s client list includes over 60 leading drug discovery companies covering a majority of the world’s largest pharmaceutical companies.
For more information, please contact: David Yin, PR Department, WuXi PharmaTech Co., Ltd. Tel: +86-21-5046-4003 Fax: +86-21-5046-1000 Email: Yin_Xiaojun@pharmatechs.com Web: http://www.pharmatechs.comhttp://www.pharmatechs-us.comhttp://www.pharmatechs.com.cn
Wuxi PharmaTech Co., Ltd.
CONTACT: David Yin, PR Department of WuXi PharmaTech Co., Ltd.,+86-21-5046-4003, or fax, +86-21-5046-1000, or Yin_Xiaojun@pharmatechs.com